May industry news: Vesper Bio announces early results for frontotemporal dementia treatment

Written by Annie Coulson (Editor)
Drug development Epilepsy and seizure Industry and business Neurodegeneration and degenerative disease News

In May’s industry news round-up: Vesper Bio announces early trial results of treatment for frontotemporal dementia; Bristol Myers Squibb obtains exclusive global license for Prothena neurodegenerative disease drug; Precisis launches brain pacemaker for drug-resistant epilepsy in the UK; Progentos Therapeutics closes series A financing to advance remyelinating treatment for multiple sclerosis; and Neuren announce positive Phase II trial data for Pitt Hopkins syndrome. Take a look at May's headlines below: Vesper Bio announces completion of single ascending dose stage in trial of treatment for frontotemporal dementia Bristol Myers Squibb claims another neuro program from Prothena Precisis launches EASEE® in the...

To view this content, please register now for access

It's completely free